Shows both agents lower potassium levels in hyperkalemia, suggesting different tolerability profiles.
Both SZC and patiromer effectively lower serum potassium and provide clinical benefits, with distinct safety considerations. Therapy selection should be guided by treatment goals and the patient's individual risk profile.
No takes yet. Share an insight, caveat, or question.
Wathanavasin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: